Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cellular Biomedicine Group, Inc.    CBMG


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Cellular Biomedicine Group Announces Appointment of Ant Financial Vice President, Gang Ji, to the Board of Directors

share with twitter share with LinkedIn share with facebook
share via e-mail
11/14/2016 | 07:45am EDT

SHANGHAI, China and CUPERTINO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the appointment of Gang Ji as a Director of the Board and the transfer of Guotong Xu, M.D., Ph.D from Director of the Board to the Scientific Advisory Board, effective November 11, 2016. Mr. Ji will join the Compensation Committee.

“We are delighted to welcome Gang Ji to the CBMG board.  Mr. Ji is an energetic and seasoned executive with over sixteen years of experience in the global investment and internet technology sectors.  He currently serves as Vice President for Ant Financial, a notable global financial technology leader, having previously transitioned from Alibaba Group where he served as Vice President responsible for strategic investments,” said Terry A. Belmont, Chairman of the Board of CBMG. “His breadth of experience in financial services, investments and high-growth industries will add powerful capabilities to our Board.  We are confident that his strategic insights and financial acumen, as well as his extensive relationships with venture capital, private equity and large institutional investors, can bolster resources for the Company’s dual technology platforms targeting unmet needs in the treatment of cancerous and degenerative diseases.”

Guotong Xu, M.D., Ph.D, who has served on the Board of Directors since November 2014, will transition to serve on the Company’s Scientific Advisory Board to lead the continued efforts of CBMG’s stem cell platforms. Dr. Xu’s regenerative medicine expertise will help advance CBMG’s multiple ongoing research programs and pipeline of therapies.

“I am delighted to join the Board of Cellular Biomedicine Group and believe that the Company’s robust and vigorous manufacturing capabilities, R&D and scientific leadership well positions CBMG to develop meaningful solutions for cancer and degenerative diseases affecting so many families in China,” commented Mr. Ji.   

About Gang Ji
Mr. Ji joined Ant Financial in January 2016 as Vice President. Mr. Ji is responsible for the global strategic investments for Ant Financial and has sixteen years of experience in investment and more than eight years of experience in the internet industry.  Before joining Ant Financial, he served Alibaba Group as Vice President, where he was responsible for strategic investment for seven years. Prior to Alibaba, Mr. Ji worked for several venture capital funds and was an auditor of KPMG.  He is a director of the publicly listed company Asia Game Technology Ltd (HKEX:8279) as well as several private technology companies. He holds a bachelor’s degree in international business management from University of International Business and Economics (Beijing).

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative and cancerous diseases.  Our developmental stem cell and Immuno-Oncology projects are the result of research and development by scientists and doctors from China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884

Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711

Primary Logo

© GlobeNewswire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
10/17CELLULAR BIOMEDICINE GROUP, INC. : Change in Directors or Principal Officers (fo..
10/03CELLULAR BIOMEDICINE GROUP, INC. : Entry into a Material Definitive Agreement, O..
10/02CELLULAR BIOMEDICINE GROUP : Announces New Facility to Expand Research and Devel..
10/01CELLULAR BIOMEDICINE GROUP : to Present at the 2019 Cantor Global Healthcare Con..
09/27CELLULAR BIOMEDICINE GROUP : 's ReJoin® Therapy Receives Stem Cell Drug Applicat..
09/27CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure (form 8-K)
09/13CELLULAR BIOMEDICINE : CBMG Hosts Meeting with Investigators to Launch AlloJoin ..
09/12CELLULAR BIOMEDICINE GROUP : Hosts Meeting with Investigators to Launch AlloJoin..
09/11CELLULAR BIOMEDICINE GROUP, INC. : Regulation FD Disclosure (form 8-K)
09/09CELLULAR BIOMEDICINE GROUP : to Present at 5th Annual CAR-TCR Summit in Boston
More news
Financials (USD)
Sales 2019 0,04 M
EBIT 2019 -48,2 M
Net income 2019 -47,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -6,20x
P/E ratio 2020 -7,05x
Capi. / Sales2019 7 629x
Capi. / Sales2020 237x
Capitalization 284 M
Duration : Period :
Cellular Biomedicine Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLULAR BIOMEDICINE GROUP
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 24,00  $
Last Close Price 14,76  $
Spread / Highest target 82,9%
Spread / Average Target 62,6%
Spread / Lowest Target 28,7%
EPS Revisions
Bi Zuo Liu CEO, Chief Financial & Accounting Officer
Terry A. Belmont Chairman
Yi Hong Yao Chief Scientific Officer
Wen Tao Liu Independent Director
Nadir Patel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.65.51%20 231
GENMAB32.04%13 665